Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Patients with chronic proteinuric nephropathies are at high risk of developing progressive renal insufficiency. There are limited controlled data on the efficacy of potentially toxic immunosuppressive therapies for many of these diseases such as immunoglobulin A nephropathy and idiopathic membranoproliferative glomerulonephritis. This limitation has not deterred healthcare providers from using such agents based on anecdotal experience. We report our experience taking care of three children with heavy proteinuria from chronic glomerular diseases. All were treated with a combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers without concomitant immunosuppression. All went into complete remission soon after starting therapy, allowing corticosteroid avoidance. The purpose of this report is to make healthcare professionals more aware of the potential success that can be achieved with this relatively nontoxic drug regimen. Larger controlled clinical trials using this strategy are needed to better evaluate the efficacy and safety of this approach in children with glomerular diseases.

Original languageEnglish (US)
Pages (from-to)1651-1654
Number of pages4
JournalPediatric Nephrology
Issue number11
StatePublished - Nov 2005


  • ACE inhibition
  • ARB
  • Dual therapy
  • IgA nephropathy
  • MPGN
  • Pediatric

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria'. Together they form a unique fingerprint.

Cite this